Nader Sanai
@NaderSanai
Followers
2K
Following
639
Statuses
228
@IvyBrainTumCtr Director. @BarrowNeuro Neurosurgical Oncologist. Leading an early-phase trials program to accelerate drug development for brain cancer.
Phoenix, AZ
Joined March 2019
@BarrowNeuro @IvyBrainTumCtr Neurosurgical Oncology Fellowship for July 2025: - 1 year duration - 1 fellow per year - CAST-approved - ACGME neurosurg grads only Pls email me to apply.
1
1
27
RT @gminniti2012: What's new in the treatment of GBM? Great talk of @DrLombardiGiu in Bologna chaired by Emilie Le Rhun, Antonio Silvani an…
0
3
0
That Dr. Spetzler flew in for this remains a source of personal pride. His legacy of inquiry, integrity, and leadership is a North Star for all of us.
#Neurosurgeon Dr. @NaderSanai, who directs the @IvyBrainTumCtr at Barrow, was presented with the 2024 #Arizona Bioscience Researcher of the Year award by #AZBio last week! Learn about Dr. Sanai's mission to defeat #braincancer in this @azbigmedia feature:
8
1
49
RT @smehtalab: So great to have three of @IvyBrainTumCtr researchers be part of this amazing @abta community. @AnChiTien @charutafurey and…
0
3
0
RT @roelverhaak: As we celebrate the approval of vorasidenib for treatment of grade II IDH-mutant, I would like to recognize those that dev…
0
26
0
RT @gminniti2012: Very inspiring talk by dr McDermott on Radiotherapy response and resistance of meningiomas at the International Neurosurg…
0
4
0
GBM cell states are fluid, but manipulable
Happy to share results from a new Phase 0 trial led by @IvyBrainTumCtr @NaderSanai @smehtalab and @Kevin_C_Johnson: Single nucleus transcriptomics, PK/PD of combined CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma
0
4
20
RT @IvyBrainTumCtr: ❗🎉 We received FDA approval to proceed with our Phase 3 clinical trial in partnership w/ @GSK! We're accelerating the G…
0
11
0
RT @PTarantinoMD: Important point on the MoA of ADCs by Pat LoRusso. Radiolabeled antibody studies showed <1% of tumor uptake with antibody…
0
39
0
Excellent study … PARP trapping is key
We are happy to share our latest paper “A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells”, out today in @CellReports. #PARP1 #PARPinhibitor #GenomicStability Hopefully not a boring thread ↓
0
0
5
Monday at #ASCO2024: Niraparib + XRT Phase 0/2 in Newly Diagnosed, MGMT-Unmethylated GBM OS= 20.3 months #Gliofocus Study coming in June: a global, label-enabling, @IvyBrainTumCtr-sponsored, head-to-head Phase 3 trial in partnership with @GSK
The Ivy Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival for newly diagnosed glioblastoma patients. Supported by @GSK, we are initiating a global, Phase 3 trial of niraparib. #ASCO24 📰:
1
14
32
RT @JacobPlieth: I'm sure no one needs reminding that #ASCO24 abstracts drop today at 5pm ET. Here's a reminder of the key presentations, t…
0
12
0
FDA-ABTC workshop on drug permeability … candid takes (this from Bill Elmquist) and non-hyperbolic discourse. Worth the Baltimore redeye.
1
0
9
Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-analysis | Oncology | JAMA | JAMA Network
0
0
9